|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2002-9-9
|
|
pubmed:abstractText |
Several controlled clinical trials have demonstrated the efficacy and safety of the lidocaine patch 5% (LP) for the treatment of postherpetic neuralgia (PHN).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0749-8047
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
18
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
297-301
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:12218500-Administration, Cutaneous,
pubmed-meshheading:12218500-Adult,
pubmed-meshheading:12218500-Analysis of Variance,
pubmed-meshheading:12218500-Anesthetics, Local,
pubmed-meshheading:12218500-Delayed-Action Preparations,
pubmed-meshheading:12218500-Double-Blind Method,
pubmed-meshheading:12218500-Drug Administration Schedule,
pubmed-meshheading:12218500-Female,
pubmed-meshheading:12218500-Herpes Zoster,
pubmed-meshheading:12218500-Humans,
pubmed-meshheading:12218500-Lidocaine,
pubmed-meshheading:12218500-Male,
pubmed-meshheading:12218500-Neuralgia,
pubmed-meshheading:12218500-Pain Measurement,
pubmed-meshheading:12218500-Pharmaceutical Vehicles,
pubmed-meshheading:12218500-Sensitivity and Specificity,
pubmed-meshheading:12218500-Treatment Outcome
|
|
pubmed:articleTitle |
The lidocaine patch 5% effectively treats all neuropathic pain qualities: results of a randomized, double-blind, vehicle-controlled, 3-week efficacy study with use of the neuropathic pain scale.
|
|
pubmed:affiliation |
Pain Clinical Research, University of Washington Multidisciplinary Pain Center, Seattle Washington, USA. galer.bradley@endo.com
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial
|
